IDEAYA Biosciences (IDYA) to Release Quarterly Earnings on Tuesday

IDEAYA Biosciences (NASDAQ:IDYA) is projected to announce its Q1 2025 earnings results before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of ($0.75) per share and revenue of $2.10 million for the quarter.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings data on Thursday, February 13th. The company reported ($1.49) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.82). The company had revenue of $7.00 million during the quarter, compared to the consensus estimate of $7.00 million. On average, analysts expect IDEAYA Biosciences to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

IDEAYA Biosciences Stock Performance

Shares of NASDAQ:IDYA opened at $20.93 on Friday. The business has a 50-day simple moving average of $17.90 and a two-hundred day simple moving average of $23.05. The firm has a market cap of $1.83 billion, a price-to-earnings ratio of -6.34 and a beta of 0.26. IDEAYA Biosciences has a fifty-two week low of $13.45 and a fifty-two week high of $44.42.

Analyst Ratings Changes

Several equities research analysts recently issued reports on IDYA shares. Stephens restated an “overweight” rating and issued a $50.00 target price on shares of IDEAYA Biosciences in a report on Friday, February 14th. Royal Bank of Canada restated an “outperform” rating and issued a $61.00 price target on shares of IDEAYA Biosciences in a research note on Wednesday, January 15th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of IDEAYA Biosciences in a research report on Monday, January 13th. Two investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, IDEAYA Biosciences currently has a consensus rating of “Moderate Buy” and an average price target of $53.58.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.